Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Metrics to compare | GLPGa | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGLPGaPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.5x | −2.8x | −0.5x | |
PEG Ratio | 0.04 | 0.06 | 0.00 | |
Price/Book | 0.7x | 1.4x | 2.6x | |
Price / LTM Sales | 6.8x | 5.8x | 3.2x | |
Upside (Analyst Target) | - | 41.3% | 41.2% | |
Fair Value Upside | Unlock | −3.7% | 6.2% | Unlock |